Main Menu

In this research endeavor, a multifaceted approach has been employed to investigate the intricate roles of CD300 family proteins in immunological processes. Lentiviral transduction of the L929 cell line with mouse and human CD300f genes, followed by puromycin selection, has established cellular models to examine the functions of these receptors. Concurrently, engineered constructs encoding extracellular domains of mouse CD300lb and CD300ld, fused with human IgG1, have been developed for the production of receptor extracellular domain proteins, facilitating studies on protein interactions.

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.

The technology involves the development of viral hemagglutinin (HA) mutants that enhance the binding affinity to sialic acid (SA) receptors on host cell surfaces. This enhanced interaction is achieved by introducing specific mutations into the HA protein, leading to increased immunogenicity and vaccine efficacy. The mutated HA proteins are then incorporated into ferritin nanoparticles, which serve as a delivery platform to enhance protein production and stability. This technology shows promise in improving vaccine design and efficacy against viral infections.

The technology focuses on stabilizing the respiratory syncytial virus (RSV) fusion (F) glycoprotein in its prefusion conformation, crucial for developing effective RSV vaccines. By introducing specific mutations (S155C-S290C, S190F, V207L) and creating interprotomer disulfides, trimer stabilization is achieved without relying on a foldon domain. This innovative approach enhances the immunogenicity of the RSV F protein, potentially leading to more potent and focused immune responses against RSV.

The technology represents a groundbreaking approach to combatting adenovirus serotype 14 (Ad14) infections by employing a live attenuated Ad14 virus to induce a robust immune response in mammals. This method is designed to provide protection against severe infections and fatalities resulting from the emergence of Ad14 variants. Currently advancing through the Clinical Phase I stage of development, this innovative strategy holds significant promise in addressing a critical public health need for effective Ad14 vaccines.

The technology involves modifying HIV-1 envelope mosaic constructs to enhance the efficacy of HIV vaccines. These modifications target specific regions of the envelope protein, aiming to elicit antibodies similar to potent anti-HIV neutralizing antibodies naturally produced during infection. By replacing highly variable patches in the V1, V2, and V3 loops with defined sequences and eliminating immune-dominant epitopes, the modified constructs induce the production of quaternary antibodies.

The technology is a groundbreaking vaccine formulation developed through a meticulous analysis of tick salivary antigens crucial for parasitism. By examining gene expression in tick salivary glands across various life stages and comparing them with ticks feeding on naturally resistant hosts, key antigens were pinpointed. These antigens target molecules that inhibit host homeostatic responses and are predicted to be secreted toxins, making them ideal candidates for inducing immunity against tick parasitism.

Platelet Factor 4 (CXCL4) has emerged as a promising natural inhibitor of HIV-1, offering new avenues for combating the AIDS virus. This discovery showcases CXCL4's ability to inhibit HIV-1 through a unique mechanism, primarily produced by activated platelets, which release it in high concentrations during blood clotting or inflammatory conditions. CXCL4's potential applications are diverse, ranging from therapeutic interventions to preventive measures.

The technology involves the discovery and development of novel compounds that inhibit the plasmodial surface anion channel (PSAC), a promising drug target for malaria treatment. These compounds have been identified through high-throughput screening as specific and potent inhibitors of PSAC, effectively killing malaria parasite cultures by blocking nutrient acquisition from human plasma. Importantly, the compounds exhibit drug-like properties and show no cytotoxicity to other cells.

This technology encompasses the discovery of broadly neutralizing antibodies against HIV-1, derived from the CAPRISA Donor CAP 256. These antibodies target the V1V2 epitope of the virus envelope and exhibit a high level of neutralization, particularly against Clade A and Clade C subtypes.